Jupirab-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief in acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and erosive esophagitis. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, improving patient compliance and symptom control. Jupirab-D Capsule SR is indicated for the treatment of acid peptic disorders accompanied by delayed gastric emptying and associated upper gastrointestinal symptoms. It should be used under medical supervision, with caution in patients with known hypersensitivity to the components or those with underlying cardiac conditions due to Domperidone’s potential to prolong the QT interval. Regular monitoring and adherence to prescribed dosage are essential to maximize therapeutic outcomes and minimize adverse effects.